Wounds in Genome: How Early Life Colibactin Producing Escherichia coli May Seed Primary Colorectal Cancer Onset

The prevalence of early-onset colorectal cancer during the previous 20 years (EOCRC diagnosed before 50 years of age) has doubled in several countries, and its causes are still mostly unknown. There is mounting evidence that early life exposure to colibactin, a genotoxin generated by Escherichia coli strains containing the polyketide synthase (pks) island, can be mutagenic. The discovery and chemistry of colibactin and the experimental evidence that it leaves a distinctive mutational signature (SBS88/ID18) are summarized in this article. These markers were enriched in early onset illness (3.3 times more common in patients diagnosed before 40 than those older than 70) and imprinted early in tumor formation according to a seminal 2025 analysis of 981 colorectal cancer genomes from 11 nations. The emerging prevalence conundrum, translational techniques (ClbP inhibition, anti-adhesion, engineered neutralization, and probiotic safety), and the safety and effectiveness of therapies are then reviewed, along with clinical prevalence investigations that include data from Iraq. E. Coli that produces colibactin provides a unique, mechanistically defined link between a gut microbe and human cancer as well as the new "windows of opportunity" model of exposure. Lastly, we list the main information gaps, which include the early-stage prevalence conundrum, population coverage, timing and acquisition of exposure, causal proof in people, and the safety and effectiveness of therapies. Colibactin-producing E. coli provides a plausible method for prevention as well as a rare, mechanistically specific connection between a gut bacterium and human cancer.

Authors

Institutions

Publication Details

Journal
NIU Journal of Health Sciences
Published
2026-11-16
DOI
https://doi.org/10.58709/niujhs.v12i3.2778
Primary Topic
Escherichia coli research studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Wounds in Genome: How Early Life Colibactin Producing Escherichia coli May Seed Primary Colorectal Cancer Onset

Sara Ayad Ahmed
5 links
NIU Journal of Health Sciences
Escherichia coli research studies
article

Wounds in Genome: How Early Life Colibactin Producing Escherichia coli May Seed Primary Colorectal Cancer Onset

Sara Ayad Ahmed
article en

Abstract

The prevalence of early-onset colorectal cancer during the previous 20 years (EOCRC diagnosed before 50 years of age) has doubled in several countries, and its causes are still mostly unknown. There is mounting evidence that early life exposure to colibactin, a genotoxin generated by Escherichia coli strains containing the polyketide synthase (pks) island, can be mutagenic. The discovery and chemistry of colibactin and the experimental evidence that it leaves a distinctive mutational signature (SBS88/ID18) are summarized in this article. These markers were enriched in early onset illness (3.3 times more common in patients diagnosed before 40 than those older than 70) and imprinted early in tumor formation according to a seminal 2025 analysis of 981 colorectal cancer genomes from 11 nations. The emerging prevalence conundrum, translational techniques (ClbP inhibition, anti-adhesion, engineered neutralization, and probiotic safety), and the safety and effectiveness of therapies are then reviewed, along with clinical prevalence investigations that include data from Iraq. E. Coli that produces colibactin provides a unique, mechanistically defined link between a gut microbe and human cancer as well as the new "windows of opportunity" model of exposure. Lastly, we list the main information gaps, which include the early-stage prevalence conundrum, population coverage, timing and acquisition of exposure, causal proof in people, and the safety and effectiveness of therapies. Colibactin-producing E. coli provides a plausible method for prevention as well as a rare, mechanistically specific connection between a gut bacterium and human cancer.

NIU Journal of Health SciencesVol. 12(3)
University of Anbar (IQ)
Good health and well-being
Escherichia coli research studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon